BETA- What are bispecific antibodies? How are they being used in blood cancer?(2026)

This video provides an in-depth overview of bispecific antibody therapies, an innovative form of immunotherapy that is transforming the treatment of blood cancers. It explains how antibodies naturally function in the immune system and how scientists engineer them to specifically recognize and attack cancer cells.

The video focuses on how bispecific antibodies differ from traditional monoclonal antibodies by targeting two sites at once—one on the cancer cell and one on an immune cell, typically a T-cell. By bringing these cells together, bispecific antibodies activate the immune system to directly kill cancer cells.

It also explores the different targets used across blood cancers such as leukemia, lymphoma, and multiple myeloma, and explains the critical role of T-cells in fighting disease. Viewers learn how these therapies compare to CAR-T cell therapy, including key differences in accessibility, manufacturing, and administration.

Additionally, the video covers how bispecific antibodies are given—often with step-up dosing to reduce immune-related side effects—and outlines potential side effects such as cytokine release syndrome (CRS), infections, and other target-specific toxicities. It also discusses treatment duration, the concept of T-cell exhaustion, and ongoing research to improve outcomes.

Overall, the video highlights how bispecific antibodies harness the body’s immune system in a powerful and targeted way, offering promising new options for patients with blood cancers.